Shanghai Zhigen Pharmaceutical Technology Co. Ltd. has identified aminoketone compounds with improved chemical stability that are potentially useful for the treatment of depression, post-traumatic stress, obsessive-compulsive disorder, pain and anxiety disorders.
The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments.
The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments.
An estimated 10% to 20% of adolescents worldwide struggle with mental health issues. According to the CDC’s most recent Youth Risk Behavior Survey, nearly 60% of teen girls in the U.S. reported feeling sad every day for at least two weeks in the previous year and 22% of high school students considered taking their own lives. Yet despite these trends, the majority of mental health conditions in young people go undiagnosed and untreated.
The first participants are being treated in a clinical trial assessing a neuromodulation system developed by Magnus Medical Inc. to treat depression. The system employs the recently FDA-cleared Saint neuromodulation technology that saw remarkable results in a clinical trial for treating major depressive disorder (MDD). The new Open Label Optimization (OLO) clinical trial is evaluating the effectiveness of this platform in conjunction with the medtech’s Magnus Neuromodulation System.
Bright Minds Biosciences Inc. has created phenethlyamines acting as 5-HT2A receptor agonists and reported to be useful for the treatment of depression and anxiety disorders.
Tonix Pharmaceuticals Holding Corp. has released data supporting the memory- and cognition-enhancing effects of TNX-4300 (estianeptine), the single (S)-isomer of tianeptine in preclinical development for depression, bipolar disorder, Alzheimer’s disease and Parkinson’s disease.
Enveric Biosciences Inc. is gearing up to begin clinical trials in generalized anxiety disorder with lead candidate, EB-373, a psilocin prodrug. Trials are expected to begin in the fourth quarter of 2023.
Enveric Biosciences Inc. is gearing up to begin clinical trials in generalized anxiety disorder with lead candidate, EB-373, a psilocin prodrug. Trials are expected to begin in the fourth quarter of 2023.
